Apogee Therapeutics Rise on Positive Data from Dermatitis Treatment Trials

Dow Jones

Jul 07, 2025

By Adriano Marchese

Apogee Therapeutics shares soared in premarket trading Monday after the company said it received positive trial data for its atopic dermatitis treatment.

Shares traded 36% higher ahead of the morning bell at $64.45.

The clinical stage biopharmaceutical company on Monday said that the second phase of the APEX clinical trial for APG777 met all primary and key secondary endpoints and exceeded trial objectives.

The 16-week trial tested the company's treatment for moderate-to-severe atopic dermatitis, a chronic, inflammatory skin condition marked by intense itching, red, inflamed scaly patches that can also interfere with sleep and general quality of life.

Some of the findings included efficacy results, which compared favorably to standard care treatments, as well as rapid itch relief and lesion reduction, and a favorable safety profile.

Write to Adriano Marchese at adriano.marchese@wsj.com

(END) Dow Jones Newswires

Apogee Therapeutics announced results from the phase 2 APEX Part A clinical trial for APG777. "Apogee Therapeutics Rise on Positive Data from Dermatitis Treatment Trials," at 6:32 a.m. ET, incorrectly said the data was from a second phase of the trial.

(END) Dow Jones Newswires

July 07, 2025 09:44 ET (13:44 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2549416535"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2549416535\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2549416535?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-07 18:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2549416535","market":"sh","top_or_hot":-1,"title":"Apogee Therapeutics Rise on Positive Data from Dermatitis Treatment Trials","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Adriano Marchese \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/APGE\">Apogee Therapeutics</a> shares soared in premarket trading Monday after the company said it received positive trial data for its atopic dermatitis treatment. \n</p>\n<p>\n  Shares traded 36% higher ahead of the morning bell at $64.45. \n</p>\n<p>\n  The clinical stage biopharmaceutical company on Monday said that the second phase of the APEX clinical trial for APG777 met all primary and key secondary endpoints and exceeded trial objectives. \n</p>\n<p>\n  The 16-week trial tested the company's treatment for moderate-to-severe atopic dermatitis, a chronic, inflammatory skin condition marked by intense itching, red, inflamed scaly patches that can also interfere with sleep and general quality of life. \n</p>\n<p>\n  Some of the findings included efficacy results, which compared favorably to standard care treatments, as well as rapid itch relief and lesion reduction, and a favorable safety profile. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n</font><font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  Apogee <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> announced results from the phase 2 APEX Part A clinical trial for APG777. \"Apogee Therapeutics Rise on Positive Data from Dermatitis Treatment Trials,\" at 6:32 a.m. ET, incorrectly said the data was from a second phase of the trial. \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 07, 2025 09:44 ET (13:44 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Apogee Therapeutics Rise on Positive Data from Dermatitis Treatment Trials</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApogee Therapeutics Rise on Positive Data from Dermatitis Treatment Trials\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-07-07 18:32</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Adriano Marchese \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/APGE\">Apogee Therapeutics</a> shares soared in premarket trading Monday after the company said it received positive trial data for its atopic dermatitis treatment. \n</p>\n<p>\n  Shares traded 36% higher ahead of the morning bell at $64.45. \n</p>\n<p>\n  The clinical stage biopharmaceutical company on Monday said that the second phase of the APEX clinical trial for APG777 met all primary and key secondary endpoints and exceeded trial objectives. \n</p>\n<p>\n  The 16-week trial tested the company's treatment for moderate-to-severe atopic dermatitis, a chronic, inflammatory skin condition marked by intense itching, red, inflamed scaly patches that can also interfere with sleep and general quality of life. \n</p>\n<p>\n  Some of the findings included efficacy results, which compared favorably to standard care treatments, as well as rapid itch relief and lesion reduction, and a favorable safety profile. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n</font><font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  Apogee <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> announced results from the phase 2 APEX Part A clinical trial for APG777. \"Apogee Therapeutics Rise on Positive Data from Dermatitis Treatment Trials,\" at 6:32 a.m. ET, incorrectly said the data was from a second phase of the trial. \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 07, 2025 09:44 ET (13:44 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"APGE","symbol_name":"Apogee Therapeutics","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2549416535","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2549416535","pubTimestamp":1751884320,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Apogee Therapeutics shares soared in premarket trading Monday after the company said it received positive trial data for its atopic dermatitis treatment.Shares traded 36% higher ahead of the morning bell at $64.45.The clinical stage biopharmaceutical company on Monday said that the second phase of the APEX clinical trial for APG777 met all primary and key secondary endpoints and exceeded trial objectives.The 16-week trial tested the company's treatment for moderate-to-severe atopic dermatitis, a chronic, inflammatory skin condition marked by intense itching, red, inflamed scaly patches that can also interfere with sleep and general quality of life.Some of the findings included efficacy results, which compared favorably to standard care treatments, as well as rapid itch relief and lesion reduction, and a favorable safety profile.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"APGE":"Apogee Therapeutics","BK4139":"生物科技"},"translate_title":"Apogee Therapeutics因皮炎治疗试验的积极数据而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"APGE":1},"content_text":"By Adriano Marchese \n\n\n \n\n\nApogee Therapeutics shares soared in premarket trading Monday after the company said it received positive trial data for its atopic dermatitis treatment. \n\n\n  Shares traded 36% higher ahead of the morning bell at $64.45. \n\n\n  The clinical stage biopharmaceutical company on Monday said that the second phase of the APEX clinical trial for APG777 met all primary and key secondary endpoints and exceeded trial objectives. \n\n\n  The 16-week trial tested the company's treatment for moderate-to-severe atopic dermatitis, a chronic, inflammatory skin condition marked by intense itching, red, inflamed scaly patches that can also interfere with sleep and general quality of life. \n\n\n  Some of the findings included efficacy results, which compared favorably to standard care treatments, as well as rapid itch relief and lesion reduction, and a favorable safety profile. \n\n\n \n\n\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n\n \n\n\n  Apogee Therapeutics announced results from the phase 2 APEX Part A clinical trial for APG777. \"Apogee Therapeutics Rise on Positive Data from Dermatitis Treatment Trials,\" at 6:32 a.m. ET, incorrectly said the data was from a second phase of the trial. \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 07, 2025 09:44 ET (13:44 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}